Ozempic

Ulta Beauty Inc. (NASDAQ:ULTA) is benefiting from the booming popularity of GLP-1 weight loss drugs, as users turn to hair and skincare products to address side effects like hair thinning and changes in skin elasticity. GLP-1 Drugs Drive Beauty Product Demand GLP-1 medications such as...

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk A/S (NYSE:NVO), marking another regulatory strike on the pharmaceutical giant over the last six months following a pattern of safety and marketing lapses. Systemic Failures In Safety Data In a letter dated March...

Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ahead for NVO stock? The class action complaint, filed in the U.S. District Court,...

Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are now available at a limited-time price of $199 per month to new self-pay patients between now and March 31, 2026. • NVO is gathering positive momentum. Check the...

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches....

The weight-loss industry that fueled one of Wall Street’s most popular ETF themes may finally be going on a crash diet. ETFs loaded with exposure to obesity-drug titans Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are tottering after President Donald Trump pledged to reduce the...

Novo Nordisk A/S (NASDAQ:NVO) is back in the headlines, and not just for its blockbuster weight-loss drug, Ozempic. President Donald Trump recently suggested a dramatic price cut for the drug, sparking some short-term market jitters. But underneath the noise, the stock is cheap at a 14 P/E, and its...

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that...

Novo Nordisk A/S (NYSE:NVO) looks ready to shake off its slump. With weight-loss pills showing blockbuster results, Ozempic proving heart-healthy benefits, and analysts flipping bullish, the stock is starting to resemble UnitedHealth Group Inc.'s (NYSE:UNH) rebound playbook. Obesity & Heart...

Hims & Hers Health Inc. (NYSE:HIMS) stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum. HIMS is encountering selling pressure. See the trading setup...

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1...

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower Tuesday after GoodRx Inc. (NASDAQ:GDRX) announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, Ozempic and Wegovy. HIMS is taking a hit from negative sentiment. See...

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European Union and China. On Thursday, the Dow Jones Industrial Average fell 1.3% to close at 39,142.23....

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...